Objectives: To examine the prevalence of sarcopenia and sarcopenic obesity (SO) as defined by different indices, including appendicular skeletal muscle mass (ASM)/height 2 , skeletal muscle mass index (SMI) and residuals for Korean adults, and to explore the association between SO and metabolic syndrome. Methods: Our study sample included 526 participants (328 women, 198 men) for whom complete data on body composition were collected using available dual X-ray absorptiometry. Modified National Cholesterol Education Program Adult Treatment Panel III criteria were used to identify the individuals with metabolic syndrome. Results: The prevalence of sarcopenia and SO is higher in older adults. Using two s.d. of ASM/height 2 below reference values from young, healthy adults as a definition of sarcopenia, the prevalence of sarcopenia and SO was 6.3% and 1.3% in older (X60 years) men and 4.1% and 0.8% in older women, respectively. The prevalence of sarcopenia using the residuals method was 15.4% in older men and 22.3% in older women. In addition, using two s.d. of SMI, the prevalence of sarcopenia and SO was 5.1% and 5.1%, respectively, in older men and 14.2% and 12.5%, respectively, in older women. Among women, SO subjects defined by the SMI had three times the risk of metabolic syndrome (odds ratios (OR) ¼ 3.24, 95% confidence interval (CI) ¼ 1.21-8.66) and non-sarcopenic obese subjects had approximately twice the risk of metabolic syndrome (OR ¼ 2.17, 95% CI ¼ 1.22-3.88) compared with normal subjects. Similar trends were observed in men. Conclusion: The prevalence and cutoff values of sarcopenia and SO in the Korean population were evaluated using different methods. Among the different indices of sarcopenia and SO, SO only defined using the SMI was associated with the risk of metabolic syndrome. As the Korean population gets older and more obese, the problematics of SO need to be elucidate.
Introduction
The epidemiological trends that characterize our generation are an obesity epidemic and the aging of the population. 1 Aging results in a progressive loss of muscle mass and strength called sarcopenia, which is Greek for 'poverty of flesh'. 2 Sarcopenia leads to functional impairment and physical disability. 3 Moreover, aging and physical disability are also related to an increase in fat mass, particularly visceral fat, 4 which is an important factor in the development of metabolic syndrome and cardiovascular disease. 5 Therefore, sarcopenia and obesity in the elderly may synergistically increase their effect on physical disability, metabolic disorders, cardiovascular disease, and mortality. 6 A combination of excess body fat and reduced muscle mass and/or strength with aging is defined as sarcopenic obesity (SO). Surplus energy intake, physical inactivity, low-grade inflammation, and changes in hormones, such as growth hormone and testosterone, may all be related to the development of SO. 6 As the obese elderly population is continuously increasing, the impact of SO is estimated to be dramatic in the next decade. 2 Korea is rapidly aging. According to the Korea National Statistical Office, 7.2% of the Korean population was aged 65 and older (i.e. elderly) in 2000. The percentage is expected to rise to 19.1% in 2025 and 34.4% in 2050. 7 The speed at which Korea is becoming an aged society is unprecedented among developed countries. Research regarding the impact of SO is essential for the development of public health programs for the increasingly elderly Korean population. Several definitions of sarcopenia and SO have already been proposed in western countries. Baumgartner et al. defined sarcopenia as reduction in appendicular skeletal muscle mass (ASM) divided by height squared (ASM/height 2 ) of two s.d. or more below the normal means for a younger reference group measured using dual X-ray absorptiometry. They defined SO as ASM/height 2 of two s.d. below the value of a young reference group and median of total body fat percentage and reported that the prevalence of SO was 4.4% in men and 3.0% in women over 60 years of age in the New Mexico Aging Process Study (NMAPS). 6, 8 In community-dwelling elderly women in Verona, Italy, Zoico et al., 9 defining SO as the two lower quintiles of ASM/height 2 plus two higher quintiles of fat mass, reported that the prevalence of SO was 12.4%. Using the same definition, Davison et al. 10 reported that the prevalence of SO was 9.6% in men and 7.4% in women from the bioelectrical impedance analysis data of NHANES III. The ASM/height 2 index is highly correlated with body mass index (BMI) as a current criterion for obesity. 11 Thus, this index primarily identified thin people as sarcopenic and could have limited applications for underestimating sarcopenia in overweight or obese subjects. 12 To overcome this limitation, Newman et al.
and
Delmonico et al. 12 proposed new criteria for sarcopenia based on the amount of lean mass being lower than expected for a given amount of fat mass using residuals from linear regression models. In addition, Janssen et al. 3 proposed a definition of sarcopenia as skeletal muscle mass index (SMI (%), skeletal muscle mass (kg)/weight (kg) Â 100) of one or two s. Despite the growing importance of SO, only a few studies evaluating the definition and prevalence of SO was performed in Caucasian populations and there have been no earlier studies in non-Caucasian populations. Furthermore, there are very few reports about a relationship between SO and metabolic disorders. We examined the prevalence of sarcopenia and SO using different definitions in Korean adults. In addition, we evaluated the associations of SO and metabolic parameters and explored the relationship between SO and metabolic syndrome.
Materials and methods

Subjects
This study is part of the Korean SO Study (KSOS), which is an ongoing epidemiologic study supported by the Korea Science and Engineering Foundation. This is a prospective, observational cohort study including a total of 591 healthy volunteers 20-88 years of age, who were recruited between September 2007 and August 2008 in Seoul, Korea. The KSOS was intended to examine the prevalence of SO in Korean adults and to evaluate the effects of SO on metabolic disorders and predict likely health outcomes. None of the participants had a history of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization), any type of diabetes, stage 2 hypertension (resting blood pressure, X160/100 mm Hg), malignant disease, severe renal, or hepatic disease. Subjects taking medications that might affect body weight or body composition were excluded. Analyses were conducted on 526 participants (328 women, 198 men) who had complete data available on body composition. Among them, young healthy volunteers (aged 20-40; 145 subjects; 54 men, 91 women) were included in a sex-specific young reference group. All participants provided written informed consent, and in accordance with the Declaration of Helsinki of the World Medical Association, the Korea University Institutional Review Board approved this study protocol.
Anthropometric and laboratory measurements BMI was calculated as weight in kilograms divided by the square of height in meters. All blood samples were obtained in the morning after a 12-h overnight fast and were immediately stored at À80 1C for subsequent assays. Serum triglycerides and HDL cholesterol were determined enzymatically using a chemistry analyzer (Hitachi 747; Tokyo, Japan). A glucose oxidase method was used to measure plasma glucose.
Definition of metabolic syndrome
Metabolic syndrome was defined according to the criteria established by the National Cholesterol Education Program Adult Treatment Panel III using the adjusted waist circumference for Asians.
14 Accordingly, participants with three or more of the following five criteria were defined as having metabolic syndrome: (i) abdominal obesity by waist circumference (defined as Asian-specific waist circumference cutoff values of X90 cm for men and X80 cm for women), 17 The SMI (%) (total skeletal muscle mass (kg)/weight (kg) Â 100) was obtained by calculating the total skeletal muscle mass adjusted by weight as described by Janssen et al. 3 As with ASM/height 2 , SMI was divided into sex-specific quintiles to facilitate the interpretation of the odds ratios (OR). Definitions of sarcopenia and SO First, sarcopenia was defined as an ASM/height 2 less than two s.d. below the sex-specific normal mean of a younger reference group 8 or the two lower quintiles in the study population. 9, 10 Alternatively, sarcopenia was defined as an SMI of two s.d. below the sex-specific mean value for a younger reference group from the entire study population. 3 Finally, the residual method was defined as the reference values of sex-specific lower 20% of the distribution of residuals between measured ASM and the ASM predicted by linear regression analysis used to model the relationship between ASM as a dependent variable, and age, height (meters), and total fat mass (kg) as independent variables.
11
A positive residual indicates a relatively muscular individual, whereas negative residual is indicative of a relatively sarcopenic individual.
12
Obesity was defined as values greater than the median total fat percentage for each sex 8 or the upper two quintiles for total body fat percentage of the study population. 9,10 SO was defined as high total body fat percentage and low relative skeletal muscle mass in the same subjects according to other earlier studies. [8] [9] [10] We classified four sarcopenia/ obesity groups by using the new criterion of SMI of two s.d. below the value of a young reference group and the upper two quintiles for total body fat percentage. The four groups included the following: normal body fat and muscle mass, sarcopenia (and normal body fat), obesity (and normal muscle mass), and SO. women, respectively. To calculate the cutoff value for the residual method, we first established a model of predicted ASM using multiple linear regression analysis by adjusting for height and total fat mass. Sex-specific equations were predicted as ASM (kg) ¼ À31.23 þ 32.84 Â height (m) þ 0.24 Â total fat mass (kg) for men and predicted as ASM (kg) ¼ À19.10 þ 21.65 Â height (m) þ 0.20 Â total fat mass (kg) for women. As a result, the sex-specific cutoff points of the lower 20% of distribution of residuals were À1.87 for men and À1.62 for women.
The cutoff values for obesity, defined as the two highest quintiles of total body fat percentage, were 20.21% for men and 31.71% for women, respectively.
Statistical analysis
Data are expressed as the mean±s.d., median and interquartile range (25%-75%), or as a percentage. Differences between groups were tested using a Student t-test or the Mann-Whitney U-test, and the w 2 -test was used to test for differences in the distribution of categorical variables. Each variable was examined for normal distribution and any positively skewed variable was log transformed. OR (95% confidence interval (CI)), predicting metabolic syndrome based on different indices for SO, were obtained from logistic regression models after controlling for potential covariates similar to gender and age. A P-value o0.05 was considered statistically significant in all analyses. All statistical results were based on two-sided tests. Data were analyzed using SPSS for Windows (Version 12.0; SPSS Inc.; Chicago, IL, USA).
Results
The characteristics of the study population The characteristics of all study subjects (20-88 years, n ¼ 526) are detailed in Table 1 . When men were compared with women, anthropometric indicators, such as height, weight, BMI, total lean body mass, ASM, ASM/height 2 , and SMI, were all greater in men than women. Total body fat percentage and HDL cholesterol were significantly greater in women. There were no differences in age and LDL cholesterol between men and women.
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Prevalence of sarcopenia
The prevalence of sarcopenia in Korean men and women was estimated using four different methods (Table 2) . When we used a cutoff point of two s.d. for ASM/height 2 in the young reference group to define sarcopenia, the prevalence in Korean men and women aged X60 years was 6.3% and 4.1%, respectively. When the cutoff point for sarcopenia was the lower two quintiles for ASM/height 2 , the prevalence of sarcopenia was much higher in both men and women (54.4% and 40.5%, respectively). Using the lowest 20th percentile of the residuals for ASM adjusted for fat mass and height, the prevalence of sarcopenia in men and women of all ages was distributed evenly. When we used a cutoff point of two s.d. for SMI in the young reference group to define sarcopenia, the prevalence in Korean men and women aged X60 years was 5.1% and 14.2%, respectively.
Prevalence of SO
The prevalence of SO in Korean men and women was estimated using three different methods ( Comparison of SO defined by ASM/height 2 index and SMI Table 4 displays the characteristics of women classified with SO using two different methods (Zoico's method and our Sarcopenia and sarcopenic obesity in Korean population TN Kim et al new method) because only a few were identified as having SO using Baumgartner's method in this study. Women subjects identified as SO using Zoico's method were of similar age, BMI, and metabolic parameters, but had significantly different other body composition parameters when compared with normal subjects. The SO group by the SMI was older, fatter, and had a greater number of metabolic risk factors than the normal group. The prevalence of metabolic syndrome was also higher in the SO group defined by the SMI compared with the normal group (Figure 1) . Although men had a lower occurrence of SO in the population, the two different SO groups in men mostly showed the characteristics similar to the female participants (Table 4) .
OR from logistic regression models predicting metabolic syndrome based on different indices for SO The associations between metabolic syndrome and different indices of sarcopenia and SO, such as ASM/height 2 , SMI, and residuals indices, are shown in Table 5 . The lowest SMI quintile was associated with a greater presence of metabolic syndrome among men and women. When sarcopenia and SO were defined using the ASM/height 2 and residuals indices, sarcopenic and SO subjects did not show significantly increased risks of metabolic syndrome compared with the normal subjects. In addition, the lowest ASM/height 2 quintile was related to fewer incidence of metabolic syndrome in both women and men. However, among women, the SO subjects identified according to the SMI had three times the risk of metabolic syndrome (OR ¼ 3.24, 95% CI ¼ 1.26-8.66) and the non-sarcopenic obese subjects had approximately twice the risk of metabolic syndrome (OR ¼ 2.17, 95% CI ¼ 1.21-3.88) compared with the normal subjects after adjustment for age. Among men, the associations between sarcopenia/obesity categories and metabolic syndrome were not statistically significant, but were otherwise similar to those in women.
Discussion
This study estimated the prevalence of sarcopenia and SO in Korean men and women using different criteria including our new method. We examined cutoff points to define sarcopenia and SO in the Korean population, which turned out to be different from those used to evaluate Caucasian population. Different definitions of sarcopenia and SO yield varying prevalence values. We found that the lowest SMI quintile is associated with a greater likelihood of metabolic syndrome in Korean population. Among the different indices of sarcopenia and SO used in our study, SO only defined using the new method was associated with the risk of metabolic syndrome. We first evaluated representative definitions of sarcopenia to investigate the prevalence of SO and to explore the relationship between SO and metabolic syndrome. Using Baumgartner's method, we found the prevalence of sarcopenia lower in Koreans compared with published results in white and Hispanic populations. 8, 16 When sarcopenia was defined as two lower quintiles of ASM/height 2 of the study Sarcopenia and sarcopenic obesity in Korean population TN Kim et al population as in Zoico's study, in this study, the prevalence of sarcopenia was 10 times higher than using Baumgartner's method according to high cutoff values in both women and men. Some investigators have tried to build control for fat mass or body mass into the indices. Among them, Janssen et al. 3 proposed to convert the absolute skeletal muscle mass (kg) to percentage of skeletal muscle mass (SMI). Using Janssen's method, the prevalence of sarcopenia in people aged 60 years or older in this study was similar to that of Janssen's study, in which the prevalence of sarcopenia was 10% in women and 7% in men, respectively. In addition, Newman et al. observed that 11.5% of obese (BMI 430 kg/m 2 ) men and 14.4% of obese women were defined as sarcopenic using the residual method. Using the lower 20% of the residuals, the prevalence of sarcopenia in this study was higher in women than in men aged 60 years or older. If the residuals or SMI indices had been adopted to identify sarcopenic individuals, the prevalence of sarcopenia would have been higher, especially in women and obese populations when compared with Baumgartner's index. The two indices can classify sarcopenia across the entire weight range of persons from thin to obese, although there are no earlier studies describing the prevalence of SO using these definitions of sarcopenia.
There was two earlier definitions of SO such as two s.d. of ASM/height 2 (sarcopenia) plus median of total body fat percentage (obesity) (Baumgartner's definition) and two lower ASM/height 2 quintiles (sarcopenia) plus two higher quintiles of total body fat percentage (obesity) (Zoico's definition) until now. 6 We added a new definition of SO (SMI: Janssen's definition of sarcopenia plus Zoico's definition of obesity) to the earlier definitions. Prevalence of SO, defined using SMI, increased with age (1.4% in men under the age of 60 years compared with 5.1% in men of 60 years or older). Corresponding figures in women were 3.3% (o60 years) and 12.5% (X60 years). On the other hand, the prevalence of SO in Koreans aged 60 or older calculated using the KSOS was very low according to Baumgartner's definition as outlined in the NMAPS and the New Mexico Elderly Health Survey (NMEHS), and the low prevalence was more noticeable in women. These results might be explained by racial and gender differences in age-related body compositional changes. Interestingly, the variation in ASM values in young and old men was greater than in women, whereas variation in values for intra-abdominal obesity indicators between young and old subjects was greater in women than in men. When the alternative definitions of SO suggested by Zoico et al. 9 and Davison et al. 10 were used, the prevalence of SO in this study was higher than that of SO in Davison's study. Moreover, the cutoff values for sarcopenia and obesity used in this study differed from those of earlier studies. ) and functional impairment and disability. 8, 16 Longitudinal results from the NMAPS showed that SO subjects at baseline were two or three times more likely to develop instrumental disability during the 8-year follow-up period than lean sarcopenic or non-SO individuals. 19 However, Zoico et al. 9 showed that high body fat and high BMI values rather than low muscle mass were associated with functional limitation. Furthermore, they reported that of the different indices of sarcopenia, only SMI predicted functional impairment and disability. The relationship between SO and metabolic abnormalities remains unknown. In cross-sectional analyses conducted as part of NMAPS, the prevalence of metabolic syndrome was highest in nonsarcopenic obese subjects, followed by SO subjects and was the lowest in sarcopenic non-obese subjects. 20 In this study, we found that SO subjects identified using the SMI had significantly elevated values for a number of components of metabolic syndrome among women compared with normal subjects. Furthermore, SO was independently associated with metabolic syndrome after adjustment for age among women. Among men, the trend similar to women was shown. Considering the increased morbidity and mortality in patients with metabolic syndrome, 21 these findings might provide a basis for future studies of health outcomes in SO patients. It is likely that the loss of muscle mass (sarcopenia) and reduced strength (dynapenia) causes reduced physical activity during aging. 22 Reductions in muscle mass and physical activity levels decreases total energy expenditures, which results in the accumulation of fat mass, especially visceral fat. 2, 23 Along with visceral fat accumulation, loss of skeletal muscle, which is the largest insulin-responsive target tissue, produces insulin resistance promoting metabolic syndrome. Moreover, an increase in visceral fat may lead to higher secretion of pro-inflammatory adipokines that further promote insulin resistance as well as potentially direct catabolic effects on muscles. 24, 25 Thus, a vicious cycle between muscle loss and fat gain changes in body composition may lead to more sarcopenia and then to further metabolic problems and inflammation. 20 The SO subjects, defined by Zoico's method, had similar BMI and metabolic parameters, whereas the SO subjects defined by our new method using the SMI had higher metabolic risks than the normal subjects. Moreover, subjects in the highest quintile for ASM/height 2 would be at a higher risk of presenting with Our study has several limitations that must be considered. First, the cross-sectional nature of this study did not allow us to identify causal relationships. Second, all of the participants in this study were relatively healthy, well-functioning men and women, as participants who had disabilities were excluded. Therefore, we may have underestimated the prevalence of SO in the Korean population as a whole. In a subsequent study to this cohort study, however, we have a plan to explore the longitudinal effects of SO on metabolic abnormalities.
In summary, we first examined the prevalence of sarcopenia and SO in Korean men and women and found considerable differences in prevalence of sarcopenia and SO depending on which definition was used. Although the prevalence of SO defined using two or more s.d. of the ASM/ height 2 index in our study population was lower than that reported in the Caucasian populations, the prevalence of sarcopenia and SO using the alternative methods, such as the SMI and residuals, was similar. We also found a significant association between the SMI quintile and metabolic syndrome. Our study showed that SO subjects, identified using the SMI, were more likely to have metabolic syndrome. Considering that the Korean population is becoming older and more obese, the problematics of sarcopenia associated with obesity or not should be more studied to establish the consequences of being diagnosed, and strategies should be developed to prevent or treat SO individuals.
